Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 5/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | HPGDS | O60760 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13710322 | 0.92 | MAPT (0.69) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL2839464 | 0.91 | HPGDS (0.70) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL19533601 | 0.90 | MAPT (0.75) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL2838868 | 0.88 | HPGDS (0.73) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL23755314 | 0.87 | MAPT (0.70) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL4712555 | 0.87 | ALPL (0.73) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL16730821 | 0.86 | MAPT (0.69) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL1816625 | 0.86 | ALPL (0.64) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL25168483 | 0.86 | ALPL (0.76) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL1413959 | 0.86 | ALPL (1.00) | ALPLMAPTRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109111434-B | Coumarin nickel ion fluorescent probe, preparation method thereof, crystal preparation method and application | 浙江外国语学院 | 2020-07-07 | — | — | CN | claimed |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-4580620-A2 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Hager Biosciences, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12275744-B2 | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | HAGER BIOSCIENCES, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240400580-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HAGER BIOSCIENCES, LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | LG CHEM, LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| WO-2024050061-A2 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4242213-A1 | BORONIC ACID COMPOUND | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| CN-116568310-A | Boric acid compounds | 株式会社LG化学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
| US-6930116-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1251848-B1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040024030-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-05 | — | — | US | disclosed |
| US-20030170858-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-09-11 | — | — | US | disclosed |
| US-6608087-B1 | Treating bacterial infections in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-19 | — | — | US | disclosed |
| EP-1251848-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1251849-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001052845-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPOATED (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052846-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | ALPL 3539/4885MAPT 3120/4885RAB9A 715/4885 |
| US-20030170858-A1 | Gyrase inhibitors and uses thereof | HSPA4, HSPA1A, GRPR | ALPL 3890/4885MAPT 4499/4885RAB9A 3889/4885 |
| US-12275744-B2 | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | HCRTR2, HCRTR1, OXTR | ALPL 4625/4885MAPT 478/4885RAB9A 2414/4885 |
| US-20240101579-A1 | BORONIC ACID COMPOUNDS | PSMB11, PSMB1, BACH1 | ALPL 3964/4885MAPT 685/4885RAB9A 931/4885 |
| US-20240400580-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | ALPL 4606/4885MAPT 454/4885RAB9A 2340/4885 |
| US-20260070922-A1 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | OPRK1, OPRD1, HCRTR2 | ALPL 4621/4885MAPT 787/4885RAB9A 2113/4885 |
| US-20040024030-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | ALPL 363/4885MAPT 4116/4885RAB9A 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.